Biologic TNF-alpha inhibitors in the treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis: a systemic review

References

• Micheletti RG, Chiesa-Fuxench Z, Noe MH, et al. Stevens-Johnson syndrome/toxic epidermal necrolysis: a multicenter retrospective study of 377 adult patients from the United States. J Invest Dermatol. 2018;138:2315–2321.
   PubMed Web of Science ®Google Scholar
• Kida Y, Kuwano K, Zhang Y, et al. Acholeplasma laidlawii up-regulates granulysin gene expression via transcription factor activator protein-1 in a human monocytic cell line, THP-1. Immunology. 2001;104:324–332.
   PubMed Web of Science ®Google Scholar
• Viard-Leveugle I, Gaide O, Jankovic D, et al. TNF-alpha and IFN-gamma are potential inducers of Fas-mediated keratinocyte apoptosis through activation of inducible nitric oxide synthase in toxic epidermal necrolysis. J Invest Dermatol. 2013;133:489–498.
   PubMed Web of Science ®Google Scholar
• Wang F, Ye Y, Luo ZY, et al. Diverse expression of TNF-α and CCL27 in serum and blister of Stevens–Johnson syndrome/toxic epidermal necrolysis. Clin Transl Allergy. 2018;8:12.
   PubMed Web of Science ®Google Scholar
• Osabe M, Tajika T, Tohkin M. Allopurinol suppresses expression of the regulatory T-cell migration factors TARC/CCL17 and MDC/CCL22 in HaCaT keratinocytes via restriction of nuclear factor-κB activation. J Appl Toxicol. 2018;38:274–283.
   PubMed Web of Science ®Google Scholar
• Bastuji-Garin S, Rzany B, Stern RS, et al. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol. 1993;129:92–96.
   PubMed Web of Science ®Google Scholar
• Fischer M, Fiedler E, Marsch WC, et al. Antitumour necrosis factor-alpha antibodies (infliximab) in the treatment of a patient with toxic epidermal necrolysis. Br J Dermatol. 2002;146:707–709.
   PubMed Web of Science ®Google Scholar
• Hunger RE, Hunziker T, Buettiker U, et al. Rapid resolution of toxic epidermal necrolysis with anti-TNF-alpha treatment. J Allergy Clin Immunol. 2005;116:923–924.
   PubMed Web of Science ®Google Scholar
• Zarate-Correa LC, Carrillo-Gomez DC, Ramirez-Escobar AF, et al. Toxic epidermal necrolysis successfully treated with infliximab. J Investig Allergol Clin Immunol. 2013;23:61–63.
   PubMed Web of Science ®Google Scholar
• Paradisi A, Abeni D, Bergamo F, et al. Etanercept therapy for toxic epidermal necrolysis. J Am Acad Dermatol. 2014;71:278–283.
   PubMed Web of Science ®Google Scholar
• Didona D, Paolino G, Garcovich S, et al. Successful use of etanercept in a case of toxic epidermal necrolysis induced by rituximab. J Eur Acad Dermatol Venereol. 2016;30:e83–e84.
   PubMed Web of Science ®Google Scholar
• Chahal D, Aleshin M, Chiu M, et al. Vaccine-induced toxic epidermal necrolysis: a case and systematic review. Dermatol Online J. 2018;24.
   PubMedGoogle Scholar
• Wang CW, Yang LY, Chen CB, et al. Randomized, controlled trial of TNF-α antagonist in CTL-mediated severe cutaneous adverse reactions. J Clin Invest. 2018;128:985–996.
   PubMed Web of Science ®Google Scholar
• Al-Shouli S, Abouchala N, Bogusz MJ, et al. Toxic epidermal necrolysis associated with high intake of sildenafil and its response to infliximab. Acta Derm Venereol. 2005;85:534–535.
   PubMed Web of Science ®Google Scholar
• Wojtkiewicz A, Wysocki M, Fortuna J, et al. Beneficial and rapid effect of infliximab on the course of toxic epidermal necrolysis. Acta Derm Venereol. 2008;88:420–421.
   PubMed Web of Science ®Google Scholar
• Burduk PK, Seredyka-Burduk M, Kazmierczak W, et al. Nasolacrimal duct obstruction after toxic epidermal necrolysis. Otolaryngol Pol. 2012;66:148–151.
   PubMedGoogle Scholar
• Kreft B, Wohlrab J, Bramsiepe I, et al. Etoricoxib-induced toxic epidermal necrolysis: successful treatment with infliximab. J Dermatol. 2010;37:904–906.
   PubMed Web of Science ®Google Scholar
• Worsnop F, Wee J, Natkunarajah J, et al. Reaction to biological drugs: infliximab for the treatment of toxic epidermal necrolysis subsequently triggering erosive lichen planus. Clin Exp Dermatol. 2012;37:879–881.
   PubMed Web of Science ®Google Scholar
• Scott-Lang V, Tidman M, McKay D. Toxic epidermal necrolysis in a child successfully treated with infliximab. Pediatr Dermatol. 2014;31:532–534.
   PubMed Web of Science ®Google Scholar
• Kreft B, Lieser U, Haase R, et al. Extensive hypertrophic scarring after toxic epidermal necrolysis in a child. Pediatr Dermatol. 2014;31:527–528.
   PubMed Web of Science ®Google Scholar
• Ganzetti G, Campanati A, Simonetti O, et al. Use of infliximab in toxic epidermal necrolysis: a still opened challenge. Giorn Ital Dermat V. 2015;150:467–471.
   PubMed Web of Science ®Google Scholar
• Wallenborn J, Fischer M. Intensive care in a patient with toxic epidermal necrolysis. Case Rep Crit Care. 2017;2017:3246196.
   PubMedGoogle Scholar
• Jiang YY, Nguyen GH, Jin HZ, et al. Methazolamide‐induced toxic epidermal necrolysis in a man carrying HLA‐B*59:01: successful treatment with infliximab and glucocorticoid. Int J Dermatol. 2018;57:494–496.
   PubMed Web of Science ®Google Scholar
• Famularo G, Di Dona B, Canzona F, et al. Etanercept for toxic epidermal necrolysis. Ann Pharmacother. 2007;41:1083–1084.
   PubMed Web of Science ®Google Scholar
• Gubinelli E, Canzona F, Tonanzi T, et al. Toxic epidermal necrolysis successfully treated with etanercept. J Dermatol. 2009;36:150–153.
   PubMed Web of Science ®Google Scholar
• Lee YY, Ko JH, Wei CH, et al. Use of etanercept to treat toxic epidermal necrolysis in a human immunodeficiency virus-positive patient. Dermatol Sin. 2013;31:78–81.
   Web of Science ®Google Scholar
• Vivar KL, Deschaine M, Messina J, et al. Epidermal programmed cell death-ligand 1 expression in TEN associated with nivolumab therapy. J Cutan Pathol. 2017;44:381–384.
   PubMed Web of Science ®Google Scholar
• Chen A, Chao K, Rodriguez L, et al. Toxic epidermal necrolysis versus cutaneous graft-versus-host disease in a hematopoietic stem cell transplant recipient: the role of elafin. Leuk Lymphoma. 2018;59:2261–2263.
   PubMed Web of Science ®Google Scholar
• Gavigan GM, Kanigsberg ND, Ramien ML. Pediatric Stevens-Johnson syndrome/toxic epidermal necrolysis halted by etanercept. J Cutan Med Surg. 2018;22:514–515.
   PubMed Web of Science ®Google Scholar
• Gaitanis G, Spyridonos P, Patmanidis K, et al. Treatment of toxic epidermal necrolysis with the combination of infliximab and high-dose intravenous immunoglobulin. Dermatology (Basel). 2012;224:134–139.
   PubMed Web of Science ®Google Scholar
• Patmanidis K, Sidiras A, Dolianitis K, et al. Combination of infliximab and high-dose intravenous immunoglobulin for toxic epidermal necrolysis: successful treatment of an elderly patient. Case Rep Dermatol Med. 2012;2012:915314.
   PubMedGoogle Scholar
• Paquet P, Jennes S, Rousseau AF, et al. Effect of N-acetylcysteine combined with infliximab on toxic epidermal necrolysis. A proof-of-concept study. Burns. 2014;40:1707–1712.
   PubMed Web of Science ®Google Scholar
• Maximova N, Granzotto M, Kiren V, et al. First description of Merkel Cell polyomavirus DNA detection in a patient with Stevens-Johnson syndrome. J Med Virol. 2013;85:918–923.
   PubMed Web of Science ®Google Scholar
• Chung WH, Hung SI, Yang JY, et al. Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis. Nat Med. 2008;14:1343–1350.
   PubMed Web of Science ®Google Scholar
• Yang C, Mosam A, Mankahla A, et al. HIV infection predisposes skin to toxic epidermal necrolysis via depletion of skin-directed CD4+ T cells. J Am Acad Dermatol. 2014;70:1096–1102.
   PubMed Web of Science ®Google Scholar
• Hefez L, Zaqhbib K, Sbidian E, et al. Post-traumatic stress disorder in Stevens-Johnson syndrome and toxic epidermal necrolysis – prevalence and risk factors. A prospective study of 31 patients. Br J Dermatol. 2018;3. DOI: 10.1111/bjd.17267.
   Google Scholar
• Lee HY, Walsh SA, Creamer D. Long-term complications of Stevens–Johnson syndrome: toxic epidermal necrolysis (SJS/TEN): the spectrum of chronic problems in patients who survive an episode of SJS/TEN necessitates multidisciplinary follow-up. Br J Dermatol. 2017;177:924–935.
   PubMed Web of Science ®Google Scholar
• Olteanu C, Shear NH, Chew HF, et al. Severe physical complications among survivors of Stevens-Johnson syndrome and toxic epidermal necrolysis. Drug Saf. 2018;41:277–284.
   PubMed Web of Science ®Google Scholar